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ABSTRACT
Introduction: There are limited findings available on KIT­negative GIST­like 
(KNGL) population. Also, KIT expression may be post­transcriptionally regulated 
by miRNA221 and miRNA222. Hence, the aim of this study is to characterize KNGL 
population, by differential gene expression, and to analyze miRNA221/222 expression 
and their prognostic value in KNGL patients.
Methods: KIT, PDGFRA, DOG1, IGF1R, MIR221 and MIR222 expression levels 
were determined by qRT­PCR. We also analyzed KIT and PDGFRA mutations, DOG1 
expression, by immunohistochemistry, along with clinical and pathological data. 
Disease­free survival (DFS) and overall survival (OS) differences were calculated 
using Log­rank test.
Results: Hierarchical cluster analyses from gene expression data identified 
two groups: group I had KIT, DOG1 and PDGFRA overexpression and IGF1R 
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underexpression and group II had overexpression of IGF1R and low expression of 
KIT, DOG1 and PDGFRA. Group II had a significant worse OS (p = 0.013) in all the 
series, and showed a tendency for worse OS (p = 0.11), when analyzed only the 
localized cases. MiRNA222 expression was significantly lower in a control subset of 
KIT­positive GIST (p < 0.001). OS was significantly worse in KNGL cases with higher 
expression of MIR221 (p = 0.028) or MIR222 (p = 0.014).
Conclusions: We identified two distinct KNGL subsets, with a different prognostic 
value. Increased levels of miRNA221/222, which are associated with worse OS, could 
explain the absence of KIT protein expression of most KNGL tumors.
INTRODUCTION
Gastrointestinal stromal tumors (GIST) constitute 
the most frequent type of digestive tract sarcoma, with 
an incidence of 10 to 14 cases per million people, each 
year [1–3]. These tumours have mesenchymal origin and 
represent a morphological and biological continuum, 
from incidentally discovered microGIST (<10 mm) to 
clinically detectable GIST [4]. Nonetheless and despite 
clinico-pathological distinct features, most GISTs share 
similar precocious genetic alterations, including KIT or 
PDGFRA gain-of-function driver mutations [5]. Indeed, 
numerous studies have confirmed that most GISTs harbour 
KIT (60–85% of cases) or PDGFRA (5%–15%) mutations. 
Additionally, between 10 to 15% of GISTs lack detectable 
mutations in both receptors, being these cases considered 
GIST WT for KIT and PDGFRA [6]. Accordingly, it seems 
reasonable that other unknown or barely characterized 
molecular pathways may be implicated in GIST 
development [7–10]. The description of new potential 
therapeutic targets in KIT-negative GIST-like (KNGL), 
might lead to novel molecular targeted therapies, as it is 
applied nowadays in KIT/ PDGFRA-driven GISTs [5, 11]. 
The positive immunostaining of KIT (CD117) has 
been a pathologic cornerstone for GIST diagnosis, since 
its redefinition in 2001 [12, 13]. Apart from mutations 
in disease-driven KIT gene, the regulatory molecular 
mechanisms of KIT expression in GISTs are not yet fully 
understood. The overexpression of KIT is rarely due to 
gene amplification, but may be related to dysregulation 
of KIT gene transcription [14]. Nonetheless, less than 5% 
of these cases show histopathological features of GIST, 
but with negative or very weak immunohistochemical 
KIT protein expression - KNGL tumors [15]. Within 
KNGL tumors two different subgroups were described 
according to pathologic and molecular findings: 1) DOG1 
positive cases, which are predominantly gastric and carry 
more frequently PDGFRA mutations; and 2) DOG1 
negative cases, that are either gastric or intestinal and with 
predominant WT genotype [16, 17]. 
Gene expression is also regulated by epigenetic 
mechanisms such as microRNAs (miRNAs). MiRNAs 
are small (17–27 nt) non-coding single stranded RNA 
molecules that negatively regulate gene expression by 
binding to imperfect complementary sites within the 
3′ untranslated region (UTR) of their mRNA target 
at the post-transcriptional level [18]. In this sense, 
miRNA221/222 cluster members have been described 
to be relevant in the regulation of KIT expression [19]. 
Bioinformatic analysis suggested that miRNA221 
and miRNA222 targeted the 3′ UTR of KIT mRNA, 
downregulating KIT protein expression, which inhibited 
normal erythropoiesis and erythroleukemic cell growth 
[19]. Based on these observations our group had shown 
the prognostic relevance of these miRNAs, in a KNGL 
series, as well as, its correlation with KIT expression 
[20]. At the same time, Koelz and colleagues published 
in 2011, that miRNA221/222 expression levels were 
significantly overexpressed in KNGL, indicating both 
publications that this miRNA cluster acts as a regulator of 
KIT expression. Nevertheless, no correlation was observed 
between the expression of miRNA221 and miRNA222 
and histomorphological parameters, tumor risk grade, or 
KIT mutation status in the past.
With the aim to better characterize this KNGL 
patient, an expression analysis of genes involved in both 
regulation of KIT expression: MIR221 and MIR222 [21]; 
as well as in the pathogenesis of GIST: KIT, PDGFRA, 
DOG1 [22, 23] and IGF1R and KDR [24, 25], along with 
a KIT and PDGFRA mutational screening and pathologic 
review was performed. The prognostic impact of these 
alterations was also analyzed. 
RESULTS
Demographics and pathologic features
A cohort of 33 (5.2%) KNGL cases, derived from a 
double-blinded reviewed collection of 624 GIST and that 
were included in the on-line Registry of the Spanish Group 
for Research on Sarcomas (GEIS), was evaluated in this 
study. One case was dropped out because the patient was 
diagnosed with GIST and died after undergoing to urgent 
laparotomy due to acute peritonitis secondary to gastric 
perforation. The male: female ratio was 1:1 with a median 
age of 61 years-old (range: 25–74). All patients were 
diagnosed between 1992 and 2003 and GIST morphology 
validated by two independent expert pathologists. 
Median follow-up was of 92 months and a total of 
14 events of metastases were registered. Five cases were 
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metastatic at diagnosis. Median size of primary tumours 
was 5 cm (ranging from 0.5 to 20 cm) and primary tumour 
locations were stomach (n = 15), small-bowel (n = 10), 
rectum (n = 4), colon (n = 1) and omentum (n = 2). Most 
of the patients (84.4%) were symptomatic at the time of 
diagnosis and the main symptoms leading to diagnosis 
was distributed as follows: constitutional syndrome 
related with anemia (5 pts), high digestive hemorrhage 
and gastrointestinal perforation (7 pts), abdominal pain (11 
pts) and others (4 pts). The median mitotic count per 50 
high-power field (HPF) was 5.5 (range 0-200/ HPF) and 
among the 32 cases analyzed, 14 showed an epithelioid 
histology (43.8%), 5 spindle cell (15.6%), 5 mixed spindle 
cell and epithelioid (15.6%), and 8 showed pleomorphic 
histology (25.0%). Of 32 cases 20 patients (62.5%) 
showed negative KIT expression, whereas 12 subjects 
(37.5%) displayed very weak KIT expression (≤ 10% of 
cells express KIT) (Supplementary Figure 1). All the cases 
included were tested for KIT in more than one paraffin 
block (median 60% of all tumour; range 16%-100%), 
avoiding the potential heterogeneity of KIT expression 
in GIST samples. Demographic, clinical and pathologic 
characteristics of KNGL cases are represented in Table 1. 
Genotype 
Mutational analysis is displayed in Table 1. No KIT 
and PDGFRA mutations were detected in 18 (56%) cases 
(WT). Seven patients (22%) displayed a KIT mutation, 
being 4 in exon 11: g.558L>R missense mutation, an 
interstitial deletion affecting codons from 552 to 559 
(g.552_559del), a deletion between codons 559 and 565 
(g.559_565del) plus a g.558L>N missense mutation, and 
a g.628S>N missense mutation; one in exon 13, another in 
exon 17 and other, a complex mutation involving part of 
intron 11. Moreover, 7 KNGL (22%) showed a PDGFRA 
mutation, six in PDGFRA exon 18 (two g842D>V and one 
g.842D>Y kinase domain mutations, one deletion 848-
851 (g.848_851del) plus a missense mutation g.852D>E, 
one deletion 849-852 (g.849_852del), and one g.827A>T 
missense mutation) and 1 case in exon 12 (g.561V>D 
juxtamembrane domain mutation). 
Eighteen cases were negative for KIT and PDGFRA 
mutations and among them 5 cases with pleomorphic 
histology and 2 with fusocellular histology displayed 
absolute negative expression of KIT and DOG1. 
Additional molecular and clinical review was performed 
to discard dedifferentiated liposarcoma (pleomorphic 
histology) and desmoid tumor (fusocellular histology) in 
these cases. Amplification of MDM2 has been described 
in a small percentage of GIST cases (3.0% to 5.3%) and 
it is associated with clinical and histological malignancy 
in this population [26, 27]. Notwithstanding, we tested 
all the 5 pleomorphic cases for MDM2 amplification 
and expression, by FISH and qRT-PCR, respectively 
(Supplementary Figure 2). Amplification of MDM2 was 
detected in one case, by FISH, and by qRT-PCR, the 
same case showed moderate expression, compared with 
a dedifferentiated liposarcoma positive control, of both 
MDM2 and CDK4, a gene well known to be amplified 
in dedifferentiated liposarcoma and described to be 
not amplified in GIST [27]. Clinical review discarded 
dedifferentiated liposarcoma of this case. Neither the 
radiological appearance, nor the tumor location indicated 
a dedifferentiated liposarcoma. The intra-peritoneal 
primary location (large intestine) is not associated with 
primary dedifferentiated liposarcoma and the typical 
transition between the well differentiated (lipomatous) 
and dedifferentiated areas was not detected neither in CAT 
scan nor in histological review of the tumor. On the other 
hand, desmoid tumor was discarded in both fusocellular 
histology cases. These cases showed cytoplasmic 
β-catenin location and it was not detected any mutation in 
the CTNNB1 gene (Supplementary Figure 3).
Survival analysis
Twenty-seven KNGL patients, with localized disease 
at diagnosis, were included in the univariate analysis 
with a median follow-up of 92 months (Table 2). Gastric 
location of the primary tumor versus other locations (p 
= 0.019) and PDGFRA mutations versus WT or KIT 
mutated (p = 0.043) were related with a significantly 
better disease-free survival (DFS). No differences were 
observed for DFS at seven years, among the sub-groups 
concerning cellularity, size, and number of mitotic figures, 
mutations in KIT exon 11 and histology. Moreover, 
tumors were assigned into risk groups according to their 
pathologic features. No differences were detected in DFS 
for Miettinen or Fletcher’s risk groups. On the other hand, 
two factors significantly influenced a worse OS: non-
gastric location (p = 0.036), age higher than 60 years 
(p = 0.03).
Gene expression analysis
All the 32 cases were included in gene expression 
analysis. For gene expression analyses, five genes were 
selected based on their relevance on GIST pathology (i.e. 
KIT, PDGFRA and DOG1) or due to their importance 
in angiogenesis and the reasonable efficiency of anti-
angiogenic therapy, such as pazopanib and sunitinib, in 
GIST (i.e. IGF1R and KDR) [28].
Unsupervised hierarchical cluster analyses obtained 
from KIT, PDGFRA, DOG1, IGF1R and KDR gene 
expression data identified two distinct groups (Figure 1): 
Group I (13 patients) had overexpression of KIT (23.46 
median fold), DOG1 (111.97 median fold) and PDGFRA 
(2.96 median fold), and underexpression of IGF1R 
(0.44 median fold); Group I cases had predominance 
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of epithelioid features, gastric location, DOG1 positive 
immunostaining (Supplementary Figure 1) and PDGFRA 
mutations. Group II (19 patients) had a higher expression 
of IGF1R (0.98 median fold), and a lower expression of 
KIT (1.76 median fold), DOG1 (2.02 median fold) and 
PDGFRA (0.26 median fold); most cases were non-gastric 
with DOG1 negative immunostaining and KIT mutated 
or WT. Expression fold of KDR was similar among both 
groups (3.39 median fold in Group I and 2.96 median 
fold in Group II). Group I and II characteristics are 
compared in Table 3. Analysis of survival between the two 
expression groups showed that Group II had significant 
worse prognosis for OS (p = 0.013), but not for DFS 
(0.19), compared to Group I (Figure 2). Survival analysis 
taking into consideration only the sub-group of KIT and 
PDGFRA mutated cases showed a trend to a worse OS 
(p = 0.123) and DFS (p = 0.099) (Supplementary Figure 4) 
of Group II compared to Group I.
MiRNA221 and miRNA222 expression
Nine additional KIT positive cases, by 
immunohistochemistry, were included in the study to 
compare the miRNAs expression levels with KNGL 
cases. Expression of both MIR221 and MIR222 was 
similar between gene expression groups I and II (Table 3). 
However, the expression of MIR221 and MIR222 was 
significantly lower in the KIT positive cases compared 
with this KNGL series (Figure 3A and 3D, respectively): 
for miRNA221 being 0.59 in KNGL vs. 0.018 in KIT 
positive control group, p = 0.057; and for miRNA222 
38.26 vs. 0.29, p < 0.001. Likewise, it seems to be an 
inverse correlation between KIT expression levels and 
MIR221 (Spearman’s ρ = –0.447; p ≤ 0.05) or MIR222 
(Spearman’s ρ = –0.419; p ≤ 0.05) in KNGL series (Table 
III). Additionally, a correlation between miRNA222 
expression levels and the mutational status of KNGL 
has also been observed (Supplementary Figure 5), in 
the sense that, WT tumors show overexpression of 
MIR222, compared with the mutated cases (p = 0.034). 
Interestingly, the OS was significantly worse for GIST 
cases with higher MIR221 (p = 0.034) or MIR222 (p = 
0.026) expression, suggesting a potential prognostic value 
for these two miRNAs in KNGL population (Figure 3B 
and 3E, respectively). Yet, no association was detected 
between DFS and MIR221 (p = 0.17) or MIR222 (p = 
0.24) expression in the same series (Figure 3C and 3F, 
respectively). On the other hand, univariate analysis 
showed that high expression of MIR221 was associated 
with a gastric location (p = 0.038) and a higher number 
Table 1: Demographics and clinical-pathologic information
Age: median (range) 61 (25–74)
Sex: male/female (%) 16 (50%)/16 (50%)
Median follow-up (months) 92 
Median size of primary tumors (cm; range) 5 (0.5–20)
Median mitotic count (/50HPF) (range) 5.5 (0–200)
Primary tumor presentation:
Localized (%)
Metastatic (%)
27 (84%)
5 (16%)
Primary tumor site:
Stomach (%)
Small-bowel (%)
Rectum (%)
Colon (%)
Omentum (%)
15 (47%)
10 (31%)
4 (13%)
1 (3%)
2 (6%)
Metastatic events (%) 14 (44%)
Subtype:
Epithelioid (%)
Others (%)
14 (44%)
18 (56%)
KIT Expression:
≤10%
Absolute negative
12 (37.5%)
20 (62.5%)
Genotype:
Wild type 
KIT mutation
PDGFRA mutation
18 (56%)
7 (22%)
7 (22%)
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of mitosis per 50 HPF (p = 0.044), whereas cases with 
high expression of MIR222 were related with complete 
negative expression of KIT (p = 0.018). MIR222 was 
also significantly expressed in Group II (p = 0.046) 
(Supplementary Table 1). 
DISCUSSION
GISTs represent a solid tumour model for molecular 
targeted therapy having approved different tyrosine kinase 
inhibitors for three lines of treatment. Usually, these 
Table 2: Univariate Survival Analysis1 
Variable DFS at 7 years  (95% CI) p
OS at 7 years  
(95% CI) p
Miettinen:
Low (n = 13)
Intermediate (n = 3)
High (n = 11)
67% (35–98)
100%
54% (25–84)
0.21
64% (36–93)
100%
70% (42–98)
0.49
Fletcher:
Low (n = 11)
Intermediate (n = 4)
High (n = 12)
56% (17–95)
100%
58% (30–86)
0.23
70% (41–999)
100%
73% (46–99)
0.34
Cellularity:
Normal (n = 17)
High (n = 10)
76% (52–100)
50% (19–81)
0.24
75% (53–96)
55% (24–82)
0.47
Size (cm):
0-6 (n = 16)
6-10 (n = 2)
>10 (n = 9)
66% (38–94)
67% (13–100)
62% (29–96)
0.82
73% (51–96)
67% (13–100)
86% (60–100)
0.85
Number of Mitosis:
0-10 MPF (n = 18)
>10 MPF (n = 9)
79% (57–100)
44% (12–77)
0.064
82% (64–100)
62% (29–96)
0.2
Location:
Gastric (n = 15)
Others (n = 12)
83% (61–100)
45% (16–75)
0.019
91% (74–100)
64% (36–92)
0.036
Age:
0-60 years (n = 14)
>60 years (n = 12)
70% (45–95)
56% (24–89)
0.39
92% (78–100)
55% (24–85)
0.03
Diagnostic Delay (Months):
0-1 (n = 14)
>1 (n = 13)
61% (36–86)
75% (45–100)
0.35
82% (63–100)
67% (36–97)
0.85
KIT Exon 11 Mutated2:
No (n = 24)
Yes (n = 3)
50% (1–99)
65% (43–88)
0.88
75% (32–100)
77% (58–97)
0.71
KIT Expression:
≤10% (n = 16)
Absolute negative (n = 11)
68% (37–99)
62% (36–89)
0.52
81% (57–100)
73% (51–96)
0.3
Subtype:
Epithelioid (n = 14) 
Others (n = 13)
69% (44–95)
61% (31–91)
0.72
92% (78–100)
57% (28–86)
0.15
Expression group3:
I (n = 13)
II (n = 14)
83% (62–100)
49% (20–78)
0.19
82% (59–100)
70% (45–95)
0.11
Mutations:
PDGFRA (n = 7)
Others (WT and KIT) (n = 20)
100%
54% (31–78)
0.043
100%
76% (57–94)
0.45
1Localized disease at diagnosis; 2 Mutations affecting codon 557 and/ or 558 3I – KIT/ PDGFR/ DOG1 positive and II – 
IGF1R positive 
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tumours arise from driver-mutations in KIT or PDGFRA 
genes [29] and it is nowadays widely accepted that KIT 
protein expression is a hallmark of GIST. Nevertheless, 
less than 5% of GIST cases lack or slightly express 
KIT protein by immunohistochemistry (IHC) [15, 17] 
which indicates that some unknown mechanisms may 
be underlying GIST pathogenesis and/ or regulating KIT 
expression. 
The hierarchical cluster analyses obtained from our 
KNGL series, distinguished two completely separated 
groups depending on the expression of KIT, PDGFRA, 
DOG1, and IGF1R. Group I was characterized by the 
overexpression of KIT, DOG1 and PDGFRA, and low 
expression of IGF1R, while Group II showed a completely 
different expression profile with overexpression of 
IGF1R and low expression of KIT, DOG1 and PDGFRA. 
IGF1R is normally overexpressed in WT GISTs [28, 
30], independently of copy number abnormalities or 
activating mutations [31], and IGF1R pathway seems to be 
involved in the differentiation of interstitial cells of Cajal 
(GIST precursor cell) immature into mature interstitial 
cells of Cajal [32], as well as in GIST pathogenesis 
and development [25, 32] and imatinib resistance [25]. 
This could indicate that in our KNGL series, cases 
overexpressing IGF1R may be associated with a more 
stem-like phenotype. Besides, overexpression of IGF1R 
and its respective ligands IGF1 and IGF2 seems to be 
prognostic factors for relapse in operated high-risk 
GIST patients [33]. Similar results were obtained in our 
study in the KNGL series, where Group II with IGF1R 
mRNA overexpression was associated with worst OS. 
Nevertheless, conflicting results had been also published 
[34, 35]. Yet, it is necessary to point out that our results 
are based on IGF1R genomic analysis, rather than 
protein evaluation by IHC, which may justify the lack of 
correlation between expression and survival. Also, it is 
critical to consider that our series includes only KNGL 
patients. 
Group I cases were predominantly epithelioid 
gastric cases, with DOG1 positive immunostaining and 
PDGFRA mutations, whereas Group II series were mostly 
non-gastric with DOG1 negative immunostaining and KIT 
mutated or WT. These results are in line with previous 
published data, where two distinct subsets of KNGL were 
described, depending on DOG1 immunostaining. DOG1 
positive cases were described to be mainly gastric and 
associated with PDGFRA mutations and DOG1 negative 
cases were described to be gastric and/ or intestinal and 
usually WT [16]. Remarkably, negative DOG-1 protein 
expression seems to be an independent prognostic factor 
for shorter OS [34, 36]. Similar results come out in our 
study, since Group II (negative DOG1 immunostaining) 
showed worse prognosis for OS. Likewise, GIST 
histological type has also been described to have a 
significant impact in GIST patient’s prognosis [37, 38], 
however with inconsistent results [39, 40]. In a report 
with 48 patients, the 5-year recurrence-free survival rate 
was significantly better among patients with spindle cell 
as compared to epithelioid or mixed histology in a series 
of KIT-expressing series [37]. Yet, univariate survival 
analysis showed that within our KNGL series, histological 
type was not a prognostic biomarker for survival, 
indicating that both DFS and OS related with GIST 
histological type may depend on KIT protein expression. 
Also, Group I features seemed to correspond with the 
typical features and behaviour of PDGFRA-driven GISTs.
Our results demonstrated that miRNA222 may 
be relevant in the regulation of KIT protein expression, 
since it is overexpressed in KNGL series, compared to 
GIST cases. MIR222 was significantly overexpressed 
in our KNGL population, whereas MIR221 showed a 
trend for signification. These results are in line with 
Figure 1: Clustering analyses according to RNA level expression. Group I (13 cases) is characterized by an overexpression of 
KIT, DOG1 and PDGFRA, and underexpression of IGF1R. Group II (19 cases) is characterized by an overexpression of IGF1R. In this 
group KIT, DOG1 and PDGFRA are clearly underexpressed. KDR expression was similar between both groups. Numbers in green indicate 
wild type genotype.
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previous published data, wherein it was demonstrated, 
by luciferase assay, that both miRNA221 and miRNA222 
were direct regulators of KIT expression, targeting the 
3′ UTR of KIT mRNA [19, 41], and that the levels of this 
two miRNAs were significantly lower in KIT-expressing 
GISTs, compared to KIT-negative GISTs [42, 43]. More 
importantly, our study demonstrated for the first time, 
that low levels of either miRNA221 or miRNA222 are 
relevant prognostic biomarkers for better OS, in KNGL 
patients. Activating mutations in KIT are present in 
about 80% of GIST [11, 40, 44] and lower expression of 
miRNA221 and miRNA222 may play a role in further 
enhancing KIT oncogenic influence on the cell in these 
cases. Yet, in KNGL cases, the role of KIT in tumour 
pathogenesis may be limited [10, 45], which indicates 
that the prognostic value of the miRNAs may also be by 
targeting other genes, besides KIT. Accordingly, targeting 
of cell cycle inhibitors CDKN1B (p27Kip1) and CDKN1C 
(p57Kip2) [46–48], or even of the tumour suppressor 
protein PTEN [49], by miRNA221 and miRNA222 may 
Table 3: Differences in pathologic, mutational and mRNA levels in gene expression groups
Groups Location Cell type DOG1  staining
Mutational  
state
KIT  
Expression
I (n = 13) Gastric: 11
Others: 2
Epithelioid: 10
Others: 3
Positive: 9
Negative: 0
N/A: 4
PDGFRA: 6
KIT: 2
Wild Type: 5
: 23.46
High: 13/13
Low: 0/13
II (n = 19) Gastric: 4
Others: 15
Epithelioid: 4
Others: 15
Positive: 1
Negative: 17
N/A: 1
PDGFRA: 1
KIT: 5
Wild Type: 13
: 1.76
High: 3/19
Low: 16/19
p < 0.001
Groups PDGFRA
 Expression
DOG1
Expression
IGF1R
Expression
MIR221
Expression
MIR222
Expression
I (n = 13) X : 2.96
High: 11/13
Low: 2/13
X : 111.97
High: 13/13
Low: 0/13
X : 0.44
High: 4/13
Low: 9/13
X : 0.02
High: 4/11
Low: 7/11
X : 3.16
High: 2/10
Low: 8/10
II (n = 19) X : 0.26
High: 5/19
Low: 14/19
X : 2.02
High: 3/19
Low: 16/19
X : 0.98
High: 12/19
Low: 7/19
X : 0.09
High: 11/18
Low: 7/18
X : 9.14
High: 11/17
Low: 6/17
p = 0.005 p < 0.001 p = 0.018 p = 0.15 p = 0.11
N/A: Not Available. X : Median.
Figure 2: Kaplan-Meyer estimation of overall survival (A) and disease-free survival (B) between gene expression groups. Group I show 
overexpression of KIT, DOG1 and PDGFRA, and low levels of IGF1R. Group II shows an inversed gene expression pattern, overexpressing 
IGF1R and underexpressing KIT, DOG1 and PDGFRA. Group I has better overall survival (p = 0.013), compared with Group II.   
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help understand the worst survival prognosis, when each 
one of the miRNAs is overexpressed in KNGL context. 
Besides, it is also important to take notice the association 
between miRNA221 overexpression and a tendency for 
a higher number of mitotic figures and, the higher levels 
of miRNA222 in Group II, overexpressing IGF1R. Thus, 
it seems that overexpression of miRNA221 could be 
associated with a higher proliferation rate in the KNGL 
series, whereas higher expression of miRNA222 could be 
associated with a more aggressive stem-like phenotype, 
which may justify the worst OS associated with both 
these miRNAs. On the other hand, the prognostic data 
of miRNA221/222 cluster members is in some way 
inconsistent with previous pre-clinical results, where 
the overexpression of miRNA221 and miRNA222, in 
GIST cell lines, inhibited cell proliferation, disturbed 
cell cycle progression and increased apoptosis [41, 50] 
by a signaling cascade that may involve KIT, AKT and 
BCL2 [50]. However, these experiments were performed 
in KIT-mutated GIST cell lines, which differ from our 
KNGL context, and therefore, it may explain the distinct 
prognostic value of miRNA221 and miRNA222 in both 
studies. 
Overall, our results described two completely 
separated groups depending on the expression of 5 genes. 
Moreover, our work showed that the overexpression of 
miRNA222, and to a lesser extent of miRNA221, could 
explain the absence of KIT protein expression in the 
biggest cohort ever analysed of KNGL cases (N = 32), 
even when KIT mRNA is overexpressed. These miRNAs 
showed in KNGL patients an interesting prognostic 
profile. Further investigation is necessary to understand 
the potential targets underlying the worse prognostic 
value associated with miRNA221/222 cluster members’ 
expression. 
METHODS
Patients
Cases selected for this study, from on line GIST 
Registry of GEIS, had to accomplish with the following 
criteria: Absence or weak (≤ 10%) protein KIT expression, 
being not received adjuvant imatinib, available paraffin 
embedded block at diagnostic time and minimum follow-
up of 6 months. Clinical and pathological data collected 
in the study were: age at diagnosis, gender, performance 
status at diagnosis, tumor location, staging, tumor size, 
type of surgery, status of surgical margins, data on 
systemic treatment(s) if any, mitotic count, necrotic 
Figure 3: MIR212 and MIR222 expression levels and Kaplan-Meyer estimation of overall or disease-free survival, 
regarding miRNAs expression levels. (A) Absolute expression levels of MIR221 in KNGL and KIT positive GIST cases (positive 
control). (B) Overall survival and (C) Disease free survival considering MIR221 gene expression. (D) Absolute expression levels of 
MIR222 in KNGL and KIT positive GIST cases. (E) Overall survival and (F) Disease-free survival concerning MIR222 gene expression. 
Error bar represents standard error. *p ≤ 0.05, **p ≤ 0.005 and ***p ≤ 0.0005.
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extension, tumor rupture, type of cellularity and cellular 
density, histologic sub-type and cellularity. The status 
at last follow-up (alive with or without disease, dead 
with or without disease), date and type of recurrence 
and any administered systemic treatment were obtained 
by follow-up from medical oncologists. Postoperative 
surveillance varied between different centers, but all 
of them consistently performed CT scan every 4–6 
months, during the first 5 years after surgery. Clinical 
data was updated and checked on a queries-based task 
between data center and medical oncologists from each 
of participating centers. Two pathologists (R.R. and J.C.), 
with expertise in GIST, were in charge of the independent 
pathologic review of the paraffin-embedded tissue blocks 
(diagnostic/ surgical specimen). The potential differential 
diagnosis as lymphoma, neuroectodermal tumors, solitary 
fibrous tumors or leiomyosarcoma, dedifferentiated 
liposarcoma or desmoid tumor, was ruled out by both the 
pathologists. 
Immunohistochemistry
KIT and DOG1 were selected for protein 
expression analysis by IHC. For all these biomarkers, 
correlation to clinical outcome was carried out. IHC 
studies were performed on formalin-fixed, paraffin-
embedded tissues (FFPE) in 3- to 4-μm sections, using the 
following antibodies: KIT [40] (1:400; A-4502; DAKO; 
Copenhagen, Denmark), DOG1 [16] (1:75; Clone K9, 
Novocastra, Leica Biosystems, Wetzlar, Germany) and 
β-catenin (610153; BD Biosciences, Qume Drive, San 
Jose, CA, USA). For KNGL classification, pathologist 
required negative o very weak KIT expression (≤ 10% of 
cells express KIT). 
Fluorescence in situ hybridization (FISH)
Histological sections of FFPE tissues were 
deparaffinized and hydrated in alcohols of decreasing 
concentrations. Antigenic recovery was performed with 
citrate at pH6. The tissue sections were co-denatured with 
proteinase K and the Vysis LSI MDM2 SO/CEP12 FISH 
probe (Abbott Molecular; E Touhy Ave, Des Plaines, IL, 
USA), at 90° C for 5 minutes, and the hybridization was 
done overnight at 37° C. After hybridization, the slides 
were washed with a 2X SSC/Tween20 solution, the nuclei 
counterstained with DAPI II (Abbott Molecular) and, 
the results were visualized in a fluorescence microscope 
equipped with the appropriate filters and a digital camera 
(Leica).
Genotype
DNA was isolated from 3- to 5-μm sections of 
FFPE tissues. After deparaffinization, the tumor tissue 
was processed with the QIAamp DNA Investigator Kit 
(Qiagen, Valencia, CA) according to the manufacturer´s 
instructions. Intronic primers were used to amplify exons 
9, 11, 13 [51] and 17 [52] of KIT, exons 12 and 18 of 
PDGFRA [5] and exon 3 of CTNNB1 [53] by PCR in a 
reaction volume of 25 µL containing 5 µL of DNA, with 
2,5 µL of buffer and MgCl2 25 mM and 0.5 µL of dNTP 
and 1.5 Units of ampliTag gold (Applied Biosystems, 
Foster City, Ca). PCR products were sequenced in F and 
R, after preheating the samples at 94° C for 6 minutes. 
The DNA was amplified over 40 cycles of 45 seconds of 
denaturation at 94° C; 1 minutes of annealing at 56° C 
and 1 minute of extension at 72° C, with an additional 
final extension step of 10 minutes. Negative controls 
were included in every set of amplifications. Bidirectional 
sequencing with specific primers was performed in an ABI 
3130 xl genetic analyzer using the BigDye Terminator 
v3.1 kit (Applied Biosystems).
Gene expression analyses
The gene expression of KIT, PDGFRA, DOG1, 
KDR, IGF1R, MIR221 and MIR222 was determined 
by qRT-PCR, using total RNA extracted, from three 
20-µm thick FFPE section, with the Recover All Total 
Nucleic Acid Isolation® (Ambion, Austin, USA). For the 
expression analysis, the following TaqMan assays were 
used: KIT (Hs00174029_m1), PDGFRA (Hs00998018_
m1), DOG1 (Hs00216121_m1), IGF1R (Hs00609576_
m1), KDR (VEGFR2) (Hs00911700_m1), MIR-221 
(Hs04231481_s1) and MIR-222 (Hs04415495_s1), and 
MDM2 (Hs1066930_m1) and CDK4 (Hs01565683_
g1). The qPCR was performed in a 7500 Fast Real 
Time PCR system (Applied Biosystems, Foster City, 
CA), with specific protocols for both quantification 
of mRNA and miRNA according to manufacturer´s 
instructions. Relative expression was calculated using 
the comparative Ct method (2−ΔΔCt) against universal 
human reference RNA (RNA pool: Universal Human 
Reference RNA; Agilent Technologies, Santa Clara, CA, 
USA). Nine KIT positive GISTs were included in gene 
expression analyses to compare miRNAs levels with 
KNGL cases.
Statistical analysis
Categorical variables were reported as relative 
frequencies (%). Quantitative variables were expressed 
as median and ranges. Comparisons between categorical 
variables and qualitative variables were performed with 
the Chi-square or Fisher exact test when appropriated, 
while in the case of quantitative variables the non-
parametric U de Mann–Whitney test was used. OS and 
DFS were measured from the date of diagnosis to the 
final event, and were estimated according to the Kaplan-
Meier method. Comparisons between the variables of 
interest were performed by the log-rank test. To analyze 
the impact on survival of MIR221 and MIR222, these 
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variables were stratified as high or low expression groups 
according to the cutoff obtained using Receiver Operating 
Characteristics (ROC) curves. All p values reported were 
2-sided, and statistical significance was defined at p = 
0.05. All the statistical procedures were performed with 
SPSS 20.0 software. 
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